{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T22:41:24Z","timestamp":1694126484994},"reference-count":39,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Tyrosine kinase inhibitors, now numbering 5 for the treatment of Philadelphia chromosome\u2013positive leukemia, have proven ability to reduce clonal disease burden rapidly, dramatically, and durably, especially in chronic myeloid leukemia in the chronic phase. Deep molecular remissions are likely in most chronic phase patients and expectations on timing of response have been developed, validated as best as possible, and evolved over time. Increasing attention has been given to the initial decline of Bcr-Abl1 transcripts and the ultimate depth of molecular remission, overshadowing but not displacing the traditional role of cytogenetic response. This chapter reviews the evolution of response milestones for chronic phase chronic myeloid leukemia and tries to answer the question of how little disease is too much.<\/jats:p>","DOI":"10.1182\/asheducation-2014.1.234","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T13:39:03Z","timestamp":1416836343000},"page":"234-239","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Goals for chronic myeloid leukemia TK inhibitor treatment: how little disease is too much?"],"prefix":"10.1182","volume":"2014","author":[{"given":"Michael J.","family":"Mauro","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"5","key":"2019111702345624000_B1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"issue":"14","key":"2019111702345624000_B2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111702345624000_B3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111702345624000_B4","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","article-title":"Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia","volume":"330","author":"Italian Cooperative Study Group on Chronic Myeloid Leukemia","year":"1994","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111702345624000_B5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111702345624000_B6","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V87.4.1549.bloodjournal8741549","article-title":"Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction","volume":"87","author":"Hochhaus","year":"1996","journal-title":"Blood"},{"issue":"4","key":"2019111702345624000_B7","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"2019111702345624000_B8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics","volume":"107","author":"Branford","year":"1999","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111702345624000_B9","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111702345624000_B10","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111702345624000_B11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.1990.tb04348.x","article-title":"Detection of residual BCR\/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction and nested primers","volume":"75","author":"Martiat","year":"1990","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111702345624000_B12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/leu.2008.183","article-title":"Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR","volume":"23","author":"Oehler","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"2019111702345624000_B13","first-page":"162","article-title":"Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment","volume":"91","author":"Colombat","year":"2006","journal-title":"Haematologica"},{"issue":"23","key":"2019111702345624000_B14","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","article-title":"BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111702345624000_B15","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2019111702345624000_B16","first-page":"1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"12","key":"2019111702345624000_B17","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford","year":"2003","journal-title":"Leukemia"},{"issue":"6","key":"2019111702345624000_B18","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia","volume":"120","author":"Wang","year":"2003","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111702345624000_B19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of Bcr-Abl1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111702345624000_B20","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"11","key":"2019111702345624000_B21","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3324\/haematol.2013.090282","article-title":"Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months","volume":"98","author":"Nazha","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"2019111702345624000_B22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/ajh.23707","article-title":"BCR\/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase","volume":"89","author":"Kim","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111702345624000_B23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and >10% Bcr-Abl1 after 3 months of imatinib depends on the rate of Bcr-Abl1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"key":"2019111702345624000_B24","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","author":"Hanfstein","journal-title":"Leukemia"},{"issue":"2","key":"2019111702345624000_B25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","article-title":"Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib","volume":"120","author":"Marin","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2019111702345624000_B26","first-page":"69","article-title":"Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study [abstract]","volume":"120","author":"Br\u00fcmmendorf","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"9","key":"2019111702345624000_B27","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111702345624000_B28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/leu.2010.197","article-title":"Do we have to kill the last CML cell?","volume":"25","author":"Ross","year":"2011","journal-title":"Leukemia"},{"issue":"10","key":"2019111702345624000_B29","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"issue":"12","key":"2019111702345624000_B30","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ajh.23560","article-title":"Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors","volume":"88","author":"Falchi","year":"2013","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111702345624000_B31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3324\/haematol.2013.095158","article-title":"Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy","volume":"99","author":"Etienne","year":"2014","journal-title":"Haematologica"},{"issue":"20","key":"2019111702345624000_B32","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2019111702345624000_B33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111702345624000_B34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"2019111702345624000_B35","first-page":"LB-6214","article-title":"First interim analysis of a pan-European stop trial using standardized molecular criteria: results of the EURO-SKI trial [abstract]","author":"Saussele","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"2019111702345624000_B36","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111702345624000_B37","first-page":"605","article-title":"The natural history of RTQ-PCR levels after the achievement of complete molecular remission (CMR): implications for \u2018stopping\u2019 studies [abstract]","volume":"118","author":"Milojkovic","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"3","key":"2019111702345624000_B38","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1182\/blood.V82.3.712.712","article-title":"Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission","volume":"82","author":"Nucifora","year":"1993","journal-title":"Blood"},{"key":"2019111702345624000_B39","doi-asserted-by":"crossref","first-page":"7023","DOI":"10.1200\/jco.2014.32.15_suppl.7023","article-title":"EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML [abstract]","volume":"32","author":"Lipton","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/234\/1250457\/bep00114000234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/234\/1250457\/bep00114000234.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T02:35:13Z","timestamp":1573958113000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2014\/1\/234\/20499\/Goals-for-chronic-myeloid-leukemia-TK-inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2014.1.234","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,5]]}}}